Literature DB >> 15942587

Primary graft dysfunction and other selected complications of lung transplantation: A single-center experience of 983 patients.

Bryan F Meyers1, Maite de la Morena, Stuart C Sweet, Elbert P Trulock, Tracey J Guthrie, Eric N Mendeloff, Charles Huddleston, Joel D Cooper, G Alexander Patterson.   

Abstract

OBJECTIVES: We sought to review the incidence and outcome of lung transplantation complications observed over 15 years at a single center.
METHODS: We performed a retrospective review from our databases, tracking outcomes after adult and pediatric lung transplantation. The 983 operations between July 1988 and September 2003 included 277 pediatric and 706 adult recipients. Bilateral (74%), unilateral (19%), and living lobar transplants (4%) comprised the bulk of this experience. Retransplantations accounted for 44 (4.5%) of the operations.
RESULTS: The groups differed by indication for transplantation. The adults included 57% with emphysema and 17% with cystic fibrosis, and the children included no patients with emphysema and 50% with cystic fibrosis. Hospital mortality was 96 (9.8%) of 983, including 46 (17%) of 277 of the children and 50 (7%) of 706 of the adults. The overall survival curves did not differ between adults and children ( P = .56). Freedom from bronchiolitis obliterans syndrome at 5 and 10 years was 45% and 18% for adults and 48% and 30% for children, respectively ( P = .53). The causes of death for adults included bronchiolitis obliterans syndrome (40%), respiratory failure (17%), and infection (14%), whereas the causes of death in children included bronchiolitis obliterans syndrome (35%), infection (28%), and respiratory failure (21%) ( P < .01). Posttransplantation lymphoproliferative disease occurred in 12% of pediatric recipients and 6% of adults ( P < .01). The frequency of treated airway complications did not differ between adults and children (9% vs 11%, P = .48). The frequency of primary graft dysfunction did not differ between children (22%) and adults (23%), despite disparity in the use of cardiopulmonary bypass.
CONCLUSION: These results highlight major complications after lung transplantation. Despite differences in underlying diagnoses and operative techniques, the 2 cohorts of patients experienced remarkably similar outcomes.

Entities:  

Mesh:

Year:  2005        PMID: 15942587     DOI: 10.1016/j.jtcvs.2005.01.022

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  12 in total

1.  Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient.

Authors:  Andi Krumbholz; Tim Sandhaus; Angela Göhlert; Albert Heim; Roland Zell; Renate Egerer; Martin Breuer; Eberhard Straube; Peter Wutzler; Andreas Sauerbrei
Journal:  Med Microbiol Immunol       Date:  2010-07-20       Impact factor: 3.402

2.  CASE 7--2014 Rescue therapy with early extracorporeal membrane oxygenation for primary graft dysfunction after bilateral lung transplantation.

Authors:  Ali M Farooki; Heidi Bazick-Cuschieri; Emily K Gordon; James C Lee; Edward C Cantu; John G Augoustides
Journal:  J Cardiothorac Vasc Anesth       Date:  2013-08-30       Impact factor: 2.628

3.  Prevention of neutrophil migration ameliorates rat lung allograft rejection.

Authors:  Shin Hirayama; Takeshi Shiraishi; Takayuki Shirakusa; Takao Higuchi; Edmund J Miller
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

Review 4.  Prevention of chronic rejection after lung transplantation.

Authors:  Anke Van Herck; Stijn E Verleden; Bart M Vanaudenaerde; Geert M Verleden; Robin Vos
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

5.  Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation.

Authors:  Yunge Zhao; Ashish K Sharma; Damien J LaPar; Irving L Kron; Gorav Ailawadi; Yuan Liu; David R Jones; Victor E Laubach; Christine L Lau
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-03-04       Impact factor: 5.464

6.  Lung transplantation for cystic fibrosis.

Authors:  Frederick R Adler; Paul Aurora; David H Barker; Mark L Barr; Laura S Blackwell; Otto H Bosma; Samuel Brown; D R Cox; Judy L Jensen; Geoffrey Kurland; George D Nossent; Alexandra L Quittner; Walter M Robinson; Sandy L Romero; Helen Spencer; Stuart C Sweet; Wim van der Bij; J Vermeulen; Erik A M Verschuuren; Elianne J L E Vrijlandt; William Walsh; Marlyn S Woo; Theodore G Liou
Journal:  Proc Am Thorac Soc       Date:  2009-12

7.  Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium.

Authors:  I Ashoor; N Najafian; Y Korin; E F Reed; T Mohanakumar; D Ikle; P S Heeger; M Lin
Journal:  Am J Transplant       Date:  2013-05-24       Impact factor: 8.086

8.  Enhanced fibrinolysis protects against lung ischemia-reperfusion injury.

Authors:  Christine L Lau; Yunge Zhao; Jiyoun Kim; Irving L Kron; Ashish Sharma; Zequan Yang; Victor E Laubach; Joel Linden; Gorav Ailawadi; David J Pinsky
Journal:  J Thorac Cardiovasc Surg       Date:  2009-05       Impact factor: 5.209

9.  Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation.

Authors:  Joseph L Bobadilla; Robert B Love; Ewa Jankowska-Gan; Qingyong Xu; Lynn D Haynes; Ruedi K Braun; Mary S Hayney; Alejandro Munoz del Rio; Keith Meyer; Daniel S Greenspan; Jose Torrealba; Kathleen M Heidler; Oscar W Cummings; Takekazu Iwata; David Brand; Robert Presson; William J Burlingham; David S Wilkes
Journal:  Am J Respir Crit Care Med       Date:  2008-01-03       Impact factor: 21.405

Review 10.  Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis.

Authors:  Jean-François Cordier
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.